BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations featuring new clinical data on the Company’s lead product candidate, atacicept, to be presented at the 59th Congress of the European Kidney Association – European Association for Dialysis and Transplantation (ERA-EDTA ) which will be held from May 19 to 22, 2022 in Paris, France, in person and virtually, at Paris Expo Porte de Versailles. Oral presentations include new clinical data from the JANUS Phase 2a clinical trial of atacicept in patients with IgA nephropathy (IgAN) and first-time renal data from a post-hoc analysis of the APRIL-SLE phase 2 study evaluating atacicept in patients with systemic lupus erythematosus (SLE) nephropathy.
About Atacicept Atacicept is an investigational recombinant fusion protein self-administered as a once-weekly subcutaneous injection that contains the soluble transmembrane activator and the calcium-modulating cyclophilin ligand interactor (TACI) receptor. which binds to cytokine B cell stimulator (BlyS) and a proliferating agent. inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B cell survival and the production of autoantibodies associated with certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a phase 2a clinical study in patients with IgAN. Vera believes that atacicept is positioned for best-in-class potential, targeting B cells and plasma cells to reduce autoantibodies and having been administered to over 1,400 patients in clinical studies across different indications.
About Vera Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered by once-weekly subcutaneous injection that blocks both B cell stimulator (BLyS) and proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating other diseases for which atacicept’s reduction of autoantibodies may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplantation. For more information, visit www.veratx.com.
Forward-Looking Statements Statements in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include regarding, among other things, Vera’s product candidates, strategy and regulatory matters. Because these statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements. Words such as “anticipates”, “will”, “expects”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Vera’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, which include, but are not limited to, risks relating to the regulatory approval process, results of prior clinical trials may not be obtained in subsequent clinical trials. , risks and uncertainties associated with Vera’s business generally, the impact of the COVID-19 pandemic, and other risks described in Vera’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date they were made and are based on management’s assumptions and estimates as of that date. Vera undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
For more information please contact:
Investor contact: [email protected]
Media Contact: Kathy Vincent Greig Communications, Inc. [email protected]
Copyright 2022 GlobeNewswire, Inc.
